AbbVie’s immunology strategy moved further into clinical execution via its acquisition deal, but separate immunology progress continues across multiple companies. Merck reported a positive clinical remission outcome for tulisokibart (anti-TL1A) in an ATLAS-UC induction-only study in ulcerative colitis. Merck said the antibody met the primary endpoint of clinical remission at week 12 based on the Modified Mayo Score, while also reporting no safety concerns in the report. The company is expected to share full details alongside ongoing induction-and-maintenance data and in regulatory-facing communications. The ATLAS-UC result matters because anti-TL1A belongs to a newer immunology class, competing with established IL-23 and JAK pathways and other emerging mechanisms aimed at differentiating efficacy durability, symptom relief, and safety. In an environment where UC treatment durability is a central commercial lever, this Phase 3 induction-only signal adds to the evidence set for TL1A-directed antibodies.